<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.2 20060430//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id><journal-title>Breast Cancer Research</journal-title><issn pub-type="ppub">1465-5411</issn><issn pub-type="epub">1465-542X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">bcr1602</article-id><article-id pub-id-type="pmid">16987421</article-id><article-id pub-id-type="doi">10.1186/bcr1602</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Cox</surname><given-names>David G</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>dcox@hsph.harvard.edu</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Blanch&#x000e9;</surname><given-names>H&#x000e9;l&#x000e8;ne</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>blanche@cephb.fr</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Pearce</surname><given-names>Celeste L</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>pearce_l@ccnt.hsc.usc.edu</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Calle</surname><given-names>Eugenia E</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>jcalle@cancer.org</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Colditz</surname><given-names>Graham A</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>graham.colditz@channing.harvard.edu</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Pike</surname><given-names>Malcolm C</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>mcpike@usc.edu</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Albanes</surname><given-names>Demetrius</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>albanesd@mail.nih.gov</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Allen</surname><given-names>Naomi E</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>naomi.allen@ceu.ox.ac.uk</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Amiano</surname><given-names>Pilar</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>epicss-san@ej-gv.es</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Berglund</surname><given-names>Goran</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>Goran.berglund@medforsk.mas.lu.se</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Boeing</surname><given-names>Heiner</given-names></name><xref ref-type="aff" rid="I10">10</xref><email>boeing@mail.dife.de</email></contrib><contrib id="A12" contrib-type="author"><name><surname>Buring</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="I11">11</xref><email>jburing@rics.bwh.harvard.edu</email></contrib><contrib id="A13" contrib-type="author"><name><surname>Burtt</surname><given-names>Noel</given-names></name><xref ref-type="aff" rid="I12">12</xref><email>burtt@genome.wi.mit.edu</email></contrib><contrib id="A14" contrib-type="author"><name><surname>Canzian</surname><given-names>Federico</given-names></name><xref ref-type="aff" rid="I13">13</xref><email>f.canzian@dkfz.de</email></contrib><contrib id="A15" contrib-type="author"><name><surname>Chanock</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="I14">14</xref><email>chanocks@mail.nih.gov</email></contrib><contrib id="A16" contrib-type="author"><name><surname>Clavel-Chapelon</surname><given-names>Fran&#x000e7;oise</given-names></name><xref ref-type="aff" rid="I15">15</xref><email>clavel@igr.fr</email></contrib><contrib id="A17" contrib-type="author"><name><surname>Feigelson</surname><given-names>Heather Spencer</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>Heather.Feigelson@cancer.org</email></contrib><contrib id="A18" contrib-type="author"><name><surname>Freedman</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="I7">7</xref><xref ref-type="aff" rid="I16">16</xref><email>freedman@broad.mit.edu</email></contrib><contrib id="A19" contrib-type="author"><name><surname>Haiman</surname><given-names>Christopher A</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>haiman@usc.edu</email></contrib><contrib id="A20" contrib-type="author"><name><surname>Hankinson</surname><given-names>Susan E</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I17">17</xref><email>nhseh@channing.harvard.edu</email></contrib><contrib id="A21" contrib-type="author"><name><surname>Henderson</surname><given-names>Brian E</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>behender@hsc.usc.edu</email></contrib><contrib id="A22" contrib-type="author"><name><surname>Hoover</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="I14">14</xref><email>hooverr@epndce.nci.nih.gov</email></contrib><contrib id="A23" contrib-type="author"><name><surname>Hunter</surname><given-names>David J</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>David.Hunter@channing.harvard.edu</email></contrib><contrib id="A24" contrib-type="author"><name><surname>Kaaks</surname><given-names>Rudolf</given-names></name><xref ref-type="aff" rid="I18">18</xref><email>kaaks@iarc.fr</email></contrib><contrib id="A25" contrib-type="author"><name><surname>Kolonel</surname><given-names>Laurence</given-names></name><xref ref-type="aff" rid="I19">19</xref><email>lkolonel@crch.hawaii.edu</email></contrib><contrib id="A26" contrib-type="author"><name><surname>Kraft</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>pkraft@hsph.harvard.edu</email></contrib><contrib id="A27" contrib-type="author"><name><surname>LeMarchand</surname><given-names>Loic</given-names></name><xref ref-type="aff" rid="I19">19</xref><email>loic@crch.hawaii.edu</email></contrib><contrib id="A28" contrib-type="author"><name><surname>Lund</surname><given-names>Eiliv</given-names></name><xref ref-type="aff" rid="I20">20</xref><email>eiliv.lund@ism.uit.no</email></contrib><contrib id="A29" contrib-type="author"><name><surname>Palli</surname><given-names>Domenico</given-names></name><xref ref-type="aff" rid="I21">21</xref><email>d.palli@cspo.it</email></contrib><contrib id="A30" contrib-type="author"><name><surname>Peeters</surname><given-names>Petra HM</given-names></name><xref ref-type="aff" rid="I22">22</xref><email>P.H.M.Peeters@umcutrecht.nl</email></contrib><contrib id="A31" contrib-type="author"><name><surname>Riboli</surname><given-names>Elio</given-names></name><xref ref-type="aff" rid="I23">23</xref><email>e.riboli@imperial.ac.uk</email></contrib><contrib id="A32" contrib-type="author"><name><surname>Stram</surname><given-names>Daniel O</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>stram@usc.edu</email></contrib><contrib id="A33" contrib-type="author"><name><surname>Thun</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>Michael.Thun@cancer.org</email></contrib><contrib id="A34" contrib-type="author"><name><surname>Tjonneland</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="I24">24</xref><email>Annet@cancer.dk</email></contrib><contrib id="A35" contrib-type="author"><name><surname>Trichopoulos</surname><given-names>Dimitrios</given-names></name><xref ref-type="aff" rid="I25">25</xref><email>dtrichop@hsph.harvard.edu</email></contrib><contrib id="A36" contrib-type="author"><name><surname>Yeager</surname><given-names>Meredith</given-names></name><xref ref-type="aff" rid="I14">14</xref><email>YeagerM@mail.nih.gov</email></contrib><contrib id="A37" contrib-type="author"><collab>the Breast and Prostate Cancer Cohort Consortium</collab></contrib></contrib-group><aff id="I1"><label>1</label>Program in Molecular and Genetic Epidemiology, Epidemiology Department, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA</aff><aff id="I2"><label>2</label>Channing Laboratory, Harvard Medical School, 181 Longwood Ave., Boston, MA, USA</aff><aff id="I3"><label>3</label>CEPH, Fondation Jean Dausset, 27 rue Juliette Dodu, 75010 Paris, France</aff><aff id="I4"><label>4</label>Keck School of Medicine, University of Southern California, East Lake Ave. Los Angeles, CA, 90089 USA</aff><aff id="I5"><label>5</label>Epidemiology and Surveillance Research American Cancer Society, 1599 Clifton Rd. NE, Atlanta, GA, 30329 USA</aff><aff id="I6"><label>6</label>Division of Cancer Epidemiology and Genetics, National Cancer Institute, Executive Blvd Rockville, MD, 20852 USA</aff><aff id="I7"><label>7</label>Cancer Research UK Epidemiology Unit, University of Oxford, Richard Doll Building, Old Road Campus Oxford, UK OX3 7LF</aff><aff id="I8"><label>8</label>Molecular and Nutritional Epidemiology Unit, Scientific Institute of Tuscany, 50131 Florence, Italy</aff><aff id="I9"><label>9</label>Department of Medicine, Lund University, 221 00 Lund, Sweden</aff><aff id="I10"><label>10</label>Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Germany</aff><aff id="I11"><label>11</label>Division of Preventive Medicine, Brigham &#x00026; Women's Hospital, Department of Medicine, Harvard Medical School, 900 Commonwealth Ave., Boston, MA 02215, USA</aff><aff id="I12"><label>12</label>Broad Institute at Harvard and the Massachusetts Institute of Technology, 7 Cambridge Center, Cambridge, MA 02142, USA</aff><aff id="I13"><label>13</label>Genomic Epidemiology Group, Division of Molecular Genetic Epidemiology, German Cancer Research Center, 69121 Heidelberg, Germany</aff><aff id="I14"><label>14</label>Core Genotyping Facility, National Cancer Institute, 8717 Grovemont Circle, Gaithersburg, MD 20892, USA</aff><aff id="I15"><label>15</label>INSERM, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France</aff><aff id="I16"><label>16</label>Dana-Farber Cancer Institute, Department of Medical Oncology, 44 Binney St., Boston, MA 02115, USA</aff><aff id="I17"><label>17</label>Department of Epidemiology, Harvard School of Public Health, 677 Huntington Ave,. Boston, MA 02115, USA</aff><aff id="I18"><label>18</label>Nutrition and Hormones Group, International Agency for Research on Cancer,150 Cours Albert Thomas, 69008 Lyon, France</aff><aff id="I19"><label>19</label>Epidemiology Program, Cancer Research Center, University of Hawaii, 1236 Lauhala St., Honolulu, HI 96813, USA</aff><aff id="I20"><label>20</label>Institute of Community Medicine, University of Troms&#x000f8;, 9037 Troms&#x000f8;, Norway</aff><aff id="I21"><label>21</label>Molecular and Nutritional Epidemiology Unit, Scientific Institute of Tuscany, 50131 Florence, Italy</aff><aff id="I22"><label>22</label>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, 3508 Utrecht, The Netherlands</aff><aff id="I23"><label>23</label>Faculty of Medicine, Division of Epidemiology, Public Health and Primary Care, Imperial College, W2 1PG London, UK</aff><aff id="I24"><label>24</label>Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark</aff><aff id="I25"><label>25</label>Department of Hygiene and Epidemiology, School of Medicine, University of Athens, 75 Mikras Asias Str., 11527 Goudi, Athens, Greece</aff><pub-date pub-type="ppub"><year>2006</year></pub-date><pub-date pub-type="epub"><day>20</day><month>9</month><year>2006</year></pub-date><volume>8</volume><issue>5</issue><fpage>R54</fpage><lpage>R54</lpage><ext-link ext-link-type="uri" xlink:href="http://breast-cancer-research.com/content/8/5/R54"/><history><date date-type="received"><day>8</day><month>6</month><year>2006</year></date><date date-type="rev-request"><day>14</day><month>8</month><year>2006</year></date><date date-type="rev-recd"><day>24</day><month>8</month><year>2006</year></date><date date-type="accepted"><day>20</day><month>9</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 Cox et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Cox et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Cox G David dcox@hsph.harvard.edu </dc:author><dc:title> A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3) </dc:title><dc:date>2006</dc:date><dcterms:bibliographicCitation>Breast Cancer Research 8(5): R54-. (2006)</dcterms:bibliographicCitation><dc:identifier type="sici">1465-5411(2006)8:5&#x0003c;R54&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1465-5411</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Introduction</title><p>Androgens have been hypothesised to influence risk of breast cancer through several possible mechanisms, including their conversion to estradiol or their binding to the oestrogen receptor and/or androgen receptor (AR) in the breast. Here, we report on the results of a large and comprehensive study of the association between genetic variation in the <italic>AR </italic>gene and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).</p></sec><sec sec-type="methods"><title>Methods</title><p>The underlying genetic variation was determined by first sequencing the coding regions of the <italic>AR </italic>gene in a panel of 95 advanced breast cancer cases. Second, a dense set of markers from the public database was genotyped in a panel of 349 healthy women. The linkage disequilibrium relationships (blocks) across the gene were then identified, and haplotype-tagging single nucleotide polymorphisms (htSNPs) were selected to capture the common genetic variation across the locus. The htSNPs were then genotyped in the nested breast cancer cases and controls from the Cancer Prevention Study II, European Prospective Investigation into Cancer and Nutrition, Multiethnic Cohort, Nurses' Health Study, and Women's Health Study cohorts (5,603 breast cancer cases and 7,480 controls).</p></sec><sec><title>Results</title><p>We found no association between any genetic variation (SNP, haplotype, or the exon 1 CAG repeat) in the <italic>AR </italic>gene and risk of breast cancer, nor were any statistical interactions with known breast cancer risk factors observed.</p></sec><sec><title>Conclusion</title><p>Among postmenopausal Caucasian women, common variants of the <italic>AR </italic>gene are not associated with risk of breast cancer.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>The effects of testosterone activity in the breast are still unknown, showing both proliferative and anti-proliferative effects <italic>in vitro </italic>[<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. Levels of testosterone, which is produced in the ovaries, adrenal gland, and peripherally in adipose tissue, either change little or decline slightly after menopause [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. In both pre- and postmenopausal women, circulating testosterone levels are associated with increased risk of breast cancer [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B17">17</xref>].</p><p>The androgen receptor (AR) protein exists as two isoforms, both arising from the same DNA sequence on the X chromosome (Xq11-q12). The shorter form of the AR protein lacks the N-terminal region, which is coded by exon 1. Within exon 1 is a tri-nucleotide CAG repeat. Although this polymorphism is associated with <italic>AR </italic>transactivation activity [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B21">21</xref>] and prostate cancer risk in some studies [<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B28">28</xref>], no clear association has been shown with breast cancer risk [<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B34">34</xref>]. The 3' UTR (untranslated region) of the <italic>AR </italic>contains sequence elements that bind to proteins involved in regulation of mRNA stability. This and other sequence-specific characteristics of <italic>AR </italic>mRNA, including putative function of the repeats in exon 1, have recently been reviewed [<xref ref-type="bibr" rid="B35">35</xref>]. The AR is expressed in the normal breast, as well as in primary and metastatic breast cancer tumours, and both the expression and protein levels are correlated with tumour invasiveness [<xref ref-type="bibr" rid="B36">36</xref>].</p><p>We hypothesised that inherited polymorphisms in genes related to sex steroid hormone synthesis, metabolism, and cell signaling could alter the function of these genes and the proteins they encode, therefore altering breast cancer risk; in this report, we present results for the AR. We used a haplotype-tagging approach, which aims to capture common variants in the <italic>AR </italic>gene. Here, we present these haplotypes and describe their association with breast cancer risk in a pooled analysis of nested case control studies from a large collaborative study, the Breast and Prostate Cancer Cohort Consortium (BPC3) [<xref ref-type="bibr" rid="B37">37</xref>], which includes 5,603 cases of breast cancer and 7,480 controls.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Study population</title><p>The BPC3 has been described in detail elsewhere [<xref ref-type="bibr" rid="B37">37</xref>]. Briefly, the consortium includes five large well-established cohorts assembled in the U.S. and Europe which have both DNA samples and extensive questionnaire information (the American Cancer Society Cancer Prevention Study II [<xref ref-type="bibr" rid="B38">38</xref>], the European Prospective Investigation into Cancer and Nutrition [EPIC] cohort [<xref ref-type="bibr" rid="B39">39</xref>], the Harvard Nurses' Health Study [NHS] [<xref ref-type="bibr" rid="B40">40</xref>] and Women's Health Study [WHS] [<xref ref-type="bibr" rid="B41">41</xref>], and the Hawaii-Los Angeles Multiethnic Cohort [MEC] [<xref ref-type="bibr" rid="B42">42</xref>]). Most women in these cohorts, with the exception of the MEC, were Caucasians of U.S. and European descent. Breast cancer cases were identified in each cohort by self-report with subsequent confirmation of the diagnosis from medical records or tumour registries and/or from linkage with population-based tumour registries (method of confirmation varied by cohort). Controls were matched to cases by ethnicity and age and, in some cohorts, additional criteria (such as country of residence in EPIC).</p></sec><sec><title>Genotyping</title><p>Coding regions of <italic>AR </italic>were sequenced in a panel of 95 advanced breast cancer cases from the MEC (19 of each ethnic group: African-American, Latino, Japanese, Native Hawaiian, and white). Thirty-two single nucleotide polymorphisms (SNPs) with minor allele frequency greater than 5% in any of the five ethnic groups or greater than 1% overall were selected from this resequencing as well as any SNP available in dbSNP to be used to select haplotype-tagging SNPs (htSNPs). These SNPs were genotyped in a reference panel of 349 healthy women from the MEC populations (including 70 whites) at the Broad Institute (Cambridge, MA, USA) using the Sequenom, Inc. (San Diego, CA, USA) and Illumina, Inc. (San Diego, CA, USA) platforms, and six htSNPs were selected to maximise R<sup>2</sup><sub>H </sub>(a measure of correlation between SNPs genotyped and the haplotypes they describe) among Caucasians, using the method of Stram <italic>et al</italic>. [<xref ref-type="bibr" rid="B43">43</xref>]. Genotyping of the six htSNPs in the breast cancer cases and controls was performed in three laboratories (University of Southern California, Los Angeles, CA, USA; Harvard School of Public Health, Boston, MA, USA; and International Agency for Research on Cancer, Lyon, France) using a fluorescent 5' endonuclease assay and the ABI-PRISM 7900 for sequence detection (Taqman) (Applied Biosystems, Foster City, CA). Initial quality control checks of the SNP assays were performed at the manufacturer (Applied Biosystems); an additional 500 test reactions were run by the BPC3. Assay characteristics for the six htSNPs for <italic>AR </italic>are available on a public website [<xref ref-type="bibr" rid="B44">44</xref>]. Sequence validation for each SNP assay was performed and 100% concordance was observed [<xref ref-type="bibr" rid="B45">45</xref>]. To assess inter-laboratory variation, each genotyping centre ran assays on a designated set of 94 samples from the Coriell Biorepository (Camden, NJ, USA), showing completion and concordance rates of greater than 99% [<xref ref-type="bibr" rid="B45">45</xref>]. The internal quality of genotype data at each genotyping centre was assessed by typing 5%&#x02013;10% blinded samples in duplicate or triplicate (depending on the study); the resulting concordance was greater than 99%. The genotyping success rate was 94% or greater for each of the six SNPs at each genotyping centre. No deviation from Hardy-Weinberg equilibrium was observed among the controls in each cohort (at the <italic>p </italic>&#x0003c; 0.01 level) for any given assay. An association among the exon 1 CAG repeat in <italic>AR</italic>, family history of breast cancer, and breast cancer risk was previously reported (1990&#x02013;96 follow-up in the NHS, 617 cases and 960 controls [<xref ref-type="bibr" rid="B46">46</xref>]). The exon 1 CAG repeat was genotyped in an additional 376 cases and 540 controls from the NHS as well as 669 cases and 674 controls from the WHS, as previously described [<xref ref-type="bibr" rid="B46">46</xref>]. Given that there is no association between the CAG repeat and breast cancer risk, and the interaction between this polymorphism and family history was not observed in this larger combined sample set (1,662 cases and 2,174 controls), we decided not to expend the resources necessary to genotype the repeat in the remaining data sets.</p></sec><sec><title>Statistical analysis</title><p>We used conditional multivariate logistic regression to estimate odds ratios (ORs) for disease in subjects with a linear (additive) scoring for zero, one, or two copies of the minor allele of each SNP. We also used conditional logistic regression with additive scoring and the most common haplotype as the referent to estimate haplotype-specific ORs, using an expectation-substitution approach to assign haplotypes based on the unphased genotype data and to account for uncertainty in assignment [<xref ref-type="bibr" rid="B47">47</xref>,<xref ref-type="bibr" rid="B48">48</xref>]. Haplotype frequencies and expected subject-specific haplotype indicators were calculated separately for each cohort (as well as by country within EPIC and race in the MEC). To test the global null hypothesis of no association between variation in <italic>AR </italic>haplotypes and htSNPs and risk of breast cancer (or subtypes defined by receptor status), we used a likelihood ratio test comparing a model with additive effects for each common haplotype (treating the most common haplotype as the referent) to the intercept-only model. We combined rare haplotypes (those with estimated individual frequencies less than 5% in all cohorts) into a single category that comprised less than 1.5% of the controls.</p><p>We considered both unadjusted conditional models and conditional models adjusting for known breast cancer risk factors. The covariates included to account for breast cancer risk factors were age at menarche (&#x02264;12 years, 13&#x02013;14 years, 15+ years), menopausal status (pre-, peri-, and postmenopausal), parity (ever/never full-term pregnancy), body mass index (BMI) (in kg/m<sup>2 </sup>as a continuous variable), and use of postmenopausal hormones (ever/never). Other common risk factors, including family history of breast cancer, personal history of benign breast disease, and age at menopause, were unavailable for large numbers of women and therefore were not included in the models. Because the results remained essentially unchanged regardless of the model used, we present results using the unadjusted conditional model. We also evaluated these covariates, restricting analyses of interaction to only those subjects with information available for variables such as family history, with categorical variables divided into quintiles. Interaction effects were evaluated using likelihood ratio testing, comparing models with the main effects of the genetic and risk variable to the model with these main effects and a multiplicative interaction term. Lastly, we tested whether the association between <italic>AR </italic>and breast cancer differed by menopausal status at diagnosis and tumour receptor (oestrogen receptor [ER] and progesterone receptor [PR]) status.</p><p>The exon 1 CAG repeat was analysed as previously reported [<xref ref-type="bibr" rid="B44">44</xref>]. Interaction <italic>p </italic>values between number of repeats and family history were calculated using likelihood ratio tests comparing the model with main effects for carrying at least one long repeat (cutoffs of &#x02265;22, 23, 25, and 27 repeats) and family history with the model containing these main effects, and an additional interaction term, with homozyotes of the &#x02265;22 allele with no family history as the reference.</p></sec></sec><sec><title>Results</title><p>Figure <xref ref-type="fig" rid="F1">1</xref> shows the genomic structure of the region around <italic>AR</italic>. One very common (approximately 70%) haplotype exists, with six lower-prevalence haplotypes being defined each by the htSNPs. The minimum R<sup>2</sup><sub>H </sub>for these six SNPs was 0.77 in the Japanese, white, and Latina samples from the SNP selection panel. However, these SNPs do not describe haplotype diversity among African-Americans (minimum R<sup>2</sup><sub>H </sub>= 0.03).</p><p>A total of 5,603 cases and 7,480 controls were available for genotyping. Table <xref ref-type="table" rid="T1">1</xref> shows some of the baseline characteristics of these cases and controls. Genotyping success for each polymorphism was greater than 94%, and samples not yielding a genotype for a given SNP were removed from analyses for that SNP. Samples not yielding at least one genotype were removed from haplotype analyses, for a total of 5,584 cases and 7,459 controls. No associations with breast cancer or heterogeneity of risk estimates across the participating cohorts were observed for any individual SNP (Table <xref ref-type="table" rid="T2">2</xref>) or haplotype tagged by these SNPs (Table <xref ref-type="table" rid="T3">3</xref>). No differences in haplotype distribution were observed between ER<sup>+ </sup>(<italic>n </italic>= 2,543) and ER<sup>- </sup>(<italic>n </italic>= 590) cases (global <italic>p </italic>value = 0.61), PR<sup>+ </sup>(<italic>n </italic>= 2,158) and PR<sup>- </sup>(<italic>n </italic>= 860) cases (global <italic>p </italic>value = 0.51), or localised (<italic>n </italic>= 2,964) and metastatic (<italic>n </italic>= 1,646) cases (global <italic>p </italic>value = 0.43). No statistically significant interactions were observed between haplotypes and common breast cancer risk factors such as family history (yes/no), BMI (&#x02264;25, &#x0003e;25), age at first full-term pregnancy (nulliparous, &#x02264;24, &#x0003e;24), or alcohol consumption (non-drinkers, &#x02264;5 g/day, &#x0003e;5 g/day) (<italic>p </italic>interaction = 0.13, 0.16, 0.14, and 0.28, respectively). These results were not materially different after excluding African-American women from the MEC (344 cases and 426 controls).</p><p>Data from further follow-up of the NHS and the WHS did not support the previous findings of interaction between the <italic>AR </italic>CAG repeat and family history on breast cancer risk in the NHS with follow-up to 1996 [<xref ref-type="bibr" rid="B46">46</xref>]. No statistically significant interactions between longer <italic>AR </italic>CAG repeat length and positive family history were observed in either the further NHS follow-up or the WHS. The decrease in risk associated with shorter repeats among family history positive cases as previously reported [<xref ref-type="bibr" rid="B46">46</xref>] was not observed (Table <xref ref-type="table" rid="T4">4</xref>).</p></sec><sec><title>Discussion</title><p>One of the main aims of the BPC3 was to overcome limitations of prior studies by increasing sample size and, therefore, power of the study. By choosing genes involved in the synthesis, metabolism, and signaling of sex hormones, we aimed to maximise the possibility of finding alleles that predispose to breast cancer. Although the <italic>AR </italic>gene is a likely candidate gene, no association between polymorphisms in the <italic>AR </italic>gene and breast cancer risk was observed, despite the large sample size (5,603 cases and 7,480 controls) and systematic approach of this study.</p><p>In a previous study [<xref ref-type="bibr" rid="B46">46</xref>], shorter alleles of the CAG repeat polymorphism in exon 1 of the <italic>AR </italic>gene were associated with decreased risk of disease in women with a family history of breast cancer in the NHS. Adding samples from further follow-up cycles of the NHS, as well as samples from the WHS, we were unable to confirm this initial finding.</p><p>Mutations in genes such as <italic>BRCA1 </italic>(breast cancer 1, early onset) and <italic>BRCA2</italic>, although highly penetrant, are of low prevalence in the general population. Very few common polymorphisms have been shown to be associated with breast cancer risk. Using a candidate gene approach to select genes of possible interest in breast cancer etiology has also yielded very few breast cancer-susceptibility loci. One possible explanation for the lack of consistent association between common polymorphisms and breast cancer risk in individual studies is that the change in risk associated with common variants is too low to detect in individual studies and results that are reported may reflect publication bias.</p><p>The 95% confidence intervals in our study were narrow and exclude a substantial association between common variants in the <italic>AR </italic>gene with breast cancer risk. A concern that is more specific to the <italic>AR </italic>gene is that, due to the gene's location on the X chromosome, X chromosome inactivation could bias risk estimates associated with a causal allele toward the null. Such bias would be especially likely if the same X chromosome (either maternal or paternal) were inactivated in all breast tissue within each woman. However, X chromosome inactivation occurs very early in embryonic development and differs between lobes within the same breast [<xref ref-type="bibr" rid="B49">49</xref>]. Assuming a low-penetrance allele (as hypothesised here), women who are heterozygous for a putative risk allele on the X chromosome are still at approximately half the risk of developing breast cancer as women who are homozygous for the same allele, as approximately half (from random inactivation) of the breast cells would not express or be exposed to the risk allele, compared with all breast cells expressing the risk allele among homozygotes. This somewhat limits the possibility that X chromosome inactivation patterns could bias risk estimates toward the null. Optimally, tumour tissue from heterozygous women would be analysed to determine which allele is inactivated; however, this is not possible in the present study, because tumour specimens are not available.</p><p>Due to the low numbers of premenopausal women in our study, we cannot exclude the <italic>AR </italic>gene as a susceptibility locus for breast cancer occurring before menopause. Additionally, although the MEC does provide information from non-Caucasian individuals, there are not a sufficient number of samples, and htSNPs selected to describe genetic variation in Caucasians is not sufficient among African-Americans to definitively exclude polymorphisms in the <italic>AR </italic>gene as breast cancer-susceptibility alleles except in Caucasians. Among the latter, neither common variants nor the CAG repeat in exon 1 of the <italic>AR </italic>gene is associated with risk of postmenopausal breast cancer.</p></sec><sec><title>Conclusion</title><p>Common polymorphisms in the <italic>AR </italic>gene are not associated with breast cancer risk among postmenopausal Caucasian women.</p></sec><sec><title>Abbreviations</title><p>AR = androgen receptor; BMI = body mass index; BPC3 = Breast and Prostate Cancer Cohort Consortium; EPIC = European Prospective Investigation into Cancer and Nutrition; ER = oestrogen receptor; htSNP = haplotype-tagging single nucleotide polymorphism; MEC = Multiethnic Cohort; NHS = Nurses' Health Study; OR = odds ratio; PR = progesterone receptor; SNP = single nucleotide polymorphism; WHS = Women's Health Study.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>DGC, H Blanch&#x000e9;, CLP, EEC, GAC, and MCP made up the writing committee for this work and were responsible for data analyses, manuscript preparation, and editing. NB and MF performed the htSNP selection and contributed substantially to manuscript editing. SC, FC, CAH, PK, DOS, and MY provided expertise in genotyping and results analyses, as well as manuscript editing. DA, NEA, PA, GB, H Boeing, JB, FC-C, HSF, SEH, BEH, RH, DJH, RK, LK, LL, EL, DP, PP, ER, MT, AT, and DT contributed substantially to sample collection and manuscript editing. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank the participants in the component cohort studies and the expert contributions of Hardeep Ranu, Craig Labadie, Lisa Cardinale, Shamika Ketkar (Harvard University), Robert Welch, Cynthia Glaser, Laurie Burdett (National Cancer Institute), Loreall Pooler (University of Southern California), and Laure Dossus and James McKay (EPIC).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Birrell</surname><given-names>SN</given-names></name><name><surname>Bentel</surname><given-names>JM</given-names></name><name><surname>Hickey</surname><given-names>TE</given-names></name><name><surname>Ricciardelli</surname><given-names>C</given-names></name><name><surname>Weger</surname><given-names>MA</given-names></name><name><surname>Horsfall</surname><given-names>DJ</given-names></name><name><surname>Tilley</surname><given-names>WD</given-names></name></person-group><article-title>Androgens induce divergent proliferative responses in human breast cancer cell lines</article-title><source>J Steroid Biochem Mol Biol</source><year>1995</year><volume>52</volume><fpage>459</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">7748811</pub-id><pub-id pub-id-type="doi">10.1016/0960-0760(95)00005-K</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marugo</surname><given-names>M</given-names></name><name><surname>Bernasconi</surname><given-names>D</given-names></name><name><surname>Miglietta</surname><given-names>L</given-names></name><name><surname>Fazzuoli</surname><given-names>L</given-names></name><name><surname>Ravera</surname><given-names>F</given-names></name><name><surname>Cassulo</surname><given-names>S</given-names></name><name><surname>Giordano</surname><given-names>G</given-names></name></person-group><article-title>Effects of dihydrotestosterone and hydroxyflutamide on androgen receptors in cultured human breast cancer cells (EVSA-T)</article-title><source>J Steroid Biochem Mol Biol</source><year>1992</year><volume>42</volume><fpage>547</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">1616884</pub-id><pub-id pub-id-type="doi">10.1016/0960-0760(92)90268-N</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ortmann</surname><given-names>J</given-names></name><name><surname>Prifti</surname><given-names>S</given-names></name><name><surname>Bohlmann</surname><given-names>MK</given-names></name><name><surname>Rehberger-Schneider</surname><given-names>S</given-names></name><name><surname>Strowitzki</surname><given-names>T</given-names></name><name><surname>Rabe</surname><given-names>T</given-names></name></person-group><article-title>Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines</article-title><source>Gynecol Endocrinol</source><year>2002</year><volume>16</volume><fpage>113</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">12012621</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rannevik</surname><given-names>G</given-names></name><name><surname>Jeppsson</surname><given-names>S</given-names></name><name><surname>Johnell</surname><given-names>O</given-names></name><name><surname>Bjerre</surname><given-names>B</given-names></name><name><surname>Laurell-Borulf</surname><given-names>Y</given-names></name><name><surname>Svanberg</surname><given-names>L</given-names></name></person-group><article-title>A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density</article-title><source>Maturitas</source><year>1995</year><volume>21</volume><fpage>103</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">7752947</pub-id><pub-id pub-id-type="doi">10.1016/0378-5122(94)00869-9</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zumoff</surname><given-names>B</given-names></name><name><surname>Strain</surname><given-names>GW</given-names></name><name><surname>Miller</surname><given-names>LK</given-names></name><name><surname>Rosner</surname><given-names>W</given-names></name></person-group><article-title>Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women</article-title><source>J Clin Endocrinol Metab</source><year>1995</year><volume>80</volume><fpage>1429</fpage><lpage>1430</lpage><pub-id pub-id-type="pmid">7714119</pub-id><pub-id pub-id-type="doi">10.1210/jc.80.4.1429</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Longcope</surname><given-names>C</given-names></name><name><surname>Franz</surname><given-names>C</given-names></name><name><surname>Morello</surname><given-names>C</given-names></name><name><surname>Baker</surname><given-names>R</given-names></name><name><surname>Johnston</surname><given-names>CC</given-names><suffix>Jr</suffix></name></person-group><article-title>Steroid and gonadotropin levels in women during the peri-menopausal years</article-title><source>Maturitas</source><year>1986</year><volume>8</volume><fpage>189</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">3097458</pub-id><pub-id pub-id-type="doi">10.1016/0378-5122(86)90025-3</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bancroft</surname><given-names>J</given-names></name><name><surname>Cawood</surname><given-names>EH</given-names></name></person-group><article-title>Androgens and the menopause: a study of 40&#x02013;60-year-old women</article-title><source>Clin Endocrinol (Oxf)</source><year>1996</year><volume>45</volume><fpage>577</fpage><lpage>587</lpage><pub-id pub-id-type="pmid">8977755</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2265.1996.00846.x</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Labrie</surname><given-names>F</given-names></name><name><surname>Belanger</surname><given-names>A</given-names></name><name><surname>Cusan</surname><given-names>L</given-names></name><name><surname>Gomez</surname><given-names>JL</given-names></name><name><surname>Candas</surname><given-names>B</given-names></name></person-group><article-title>Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging</article-title><source>J Clin Endocrinol Metab</source><year>1997</year><volume>82</volume><fpage>2396</fpage><lpage>2402</lpage><pub-id pub-id-type="pmid">9253307</pub-id><pub-id pub-id-type="doi">10.1210/jc.82.8.2396</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>HG</given-names></name><name><surname>Dudley</surname><given-names>EC</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Dennerstein</surname><given-names>L</given-names></name><name><surname>Hopper</surname><given-names>JL</given-names></name></person-group><article-title>A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition</article-title><source>J Clin Endocrinol Metab</source><year>2000</year><volume>85</volume><fpage>2832</fpage><lpage>2838</lpage><pub-id pub-id-type="pmid">10946891</pub-id><pub-id pub-id-type="doi">10.1210/jc.85.8.2832</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cauley</surname><given-names>JA</given-names></name><name><surname>Lucas</surname><given-names>FL</given-names></name><name><surname>Kuller</surname><given-names>LH</given-names></name><name><surname>Stone</surname><given-names>K</given-names></name><name><surname>Browner</surname><given-names>W</given-names></name><name><surname>Cummings</surname><given-names>SR</given-names></name></person-group><article-title>Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group</article-title><source>Ann Intern Med</source><year>1999</year><volume>130</volume><fpage>270</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">10068384</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hankinson</surname><given-names>SE</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Colditz</surname><given-names>GA</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Spiegelman</surname><given-names>D</given-names></name><name><surname>Barbieri</surname><given-names>RL</given-names></name><name><surname>Speizer</surname><given-names>FE</given-names></name></person-group><article-title>Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women</article-title><source>J Natl Cancer Inst</source><year>1998</year><volume>90</volume><fpage>1292</fpage><lpage>1299</lpage><pub-id pub-id-type="pmid">9731736</pub-id><pub-id pub-id-type="doi">10.1093/jnci/90.17.1292</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeleniuch-Jacquotte</surname><given-names>A</given-names></name><name><surname>Bruning</surname><given-names>PF</given-names></name><name><surname>Bonfrer</surname><given-names>JM</given-names></name><name><surname>Koenig</surname><given-names>KL</given-names></name><name><surname>Shore</surname><given-names>RE</given-names></name><name><surname>Kim</surname><given-names>MY</given-names></name><name><surname>Pasternack</surname><given-names>BS</given-names></name><name><surname>Toniolo</surname><given-names>P</given-names></name></person-group><article-title>Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women</article-title><source>Am J Epidemiol</source><year>1997</year><volume>145</volume><fpage>1030</fpage><lpage>1038</lpage><pub-id pub-id-type="pmid">9169912</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>HV</given-names></name><name><surname>Key</surname><given-names>TJ</given-names></name><name><surname>Allen</surname><given-names>DS</given-names></name><name><surname>Moore</surname><given-names>JW</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Fentiman</surname><given-names>IS</given-names></name><name><surname>Wang</surname><given-names>DY</given-names></name></person-group><article-title>A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey</article-title><source>Br J Cancer</source><year>1997</year><volume>76</volume><fpage>401</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">9252211</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berrino</surname><given-names>F</given-names></name><name><surname>Muti</surname><given-names>P</given-names></name><name><surname>Micheli</surname><given-names>A</given-names></name><name><surname>Bolelli</surname><given-names>G</given-names></name><name><surname>Krogh</surname><given-names>V</given-names></name><name><surname>Sciajno</surname><given-names>R</given-names></name><name><surname>Pisani</surname><given-names>P</given-names></name><name><surname>Panico</surname><given-names>S</given-names></name><name><surname>Secreto</surname><given-names>G</given-names></name></person-group><article-title>Serum sex hormone levels after menopause and subsequent breast cancer</article-title><source>J Natl Cancer Inst</source><year>1996</year><volume>88</volume><fpage>291</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">8614008</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorgan</surname><given-names>JF</given-names></name><name><surname>Longcope</surname><given-names>C</given-names></name><name><surname>Stephenson</surname><given-names>HE</given-names><suffix>Jr</suffix></name><name><surname>Falk</surname><given-names>RT</given-names></name><name><surname>Miller</surname><given-names>R</given-names></name><name><surname>Franz</surname><given-names>C</given-names></name><name><surname>Kahle</surname><given-names>L</given-names></name><name><surname>Campbell</surname><given-names>WS</given-names></name><name><surname>Tangrea</surname><given-names>JA</given-names></name><name><surname>Schatzkin</surname><given-names>A</given-names></name></person-group><article-title>Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>1996</year><volume>5</volume><fpage>533</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">8827358</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garland</surname><given-names>CF</given-names></name><name><surname>Friedlander</surname><given-names>NJ</given-names></name><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><name><surname>Khaw</surname><given-names>KT</given-names></name></person-group><article-title>Sex hormones and postmenopausal breast cancer: a prospective study in an adult community</article-title><source>Am J Epidemiol</source><year>1992</year><volume>135</volume><fpage>1220</fpage><lpage>1230</lpage><pub-id pub-id-type="pmid">1626540</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wysowski</surname><given-names>DK</given-names></name><name><surname>Comstock</surname><given-names>GW</given-names></name><name><surname>Helsing</surname><given-names>KJ</given-names></name><name><surname>Lau</surname><given-names>HL</given-names></name></person-group><article-title>Sex hormone levels in serum in relation to the development of breast cancer</article-title><source>Am J Epidemiol</source><year>1987</year><volume>125</volume><fpage>791</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">3565354</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chamberlain</surname><given-names>NL</given-names></name><name><surname>Driver</surname><given-names>ED</given-names></name><name><surname>Miesfeld</surname><given-names>RL</given-names></name></person-group><article-title>The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function</article-title><source>Nucleic Acids Res</source><year>1994</year><volume>22</volume><fpage>3181</fpage><lpage>3186</lpage><pub-id pub-id-type="pmid">8065934</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kazemi-Esfarjani</surname><given-names>P</given-names></name><name><surname>Trifiro</surname><given-names>MA</given-names></name><name><surname>Pinsky</surname><given-names>L</given-names></name></person-group><article-title>Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies</article-title><source>Hum Mol Genet</source><year>1995</year><volume>4</volume><fpage>523</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">7633399</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tut</surname><given-names>TG</given-names></name><name><surname>Ghadessy</surname><given-names>FJ</given-names></name><name><surname>Trifiro</surname><given-names>MA</given-names></name><name><surname>Pinsky</surname><given-names>L</given-names></name><name><surname>Yong</surname><given-names>EL</given-names></name></person-group><article-title>Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility</article-title><source>J Clin Endocrinol Metab</source><year>1997</year><volume>82</volume><fpage>3777</fpage><lpage>3782</lpage><pub-id pub-id-type="pmid">9360540</pub-id><pub-id pub-id-type="doi">10.1210/jc.82.11.3777</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Irvine</surname><given-names>RA</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>MC</given-names></name><name><surname>Ross</surname><given-names>RK</given-names></name><name><surname>Stallcup</surname><given-names>MR</given-names></name><name><surname>Coetzee</surname><given-names>GA</given-names></name></person-group><article-title>Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length</article-title><source>Hum Mol Genet</source><year>2000</year><volume>9</volume><fpage>267</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">10607837</pub-id><pub-id pub-id-type="doi">10.1093/hmg/9.2.267</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giovannucci</surname><given-names>E</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Krithivas</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Dahl</surname><given-names>D</given-names></name><name><surname>Brufsky</surname><given-names>A</given-names></name><name><surname>Talcott</surname><given-names>J</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name></person-group><article-title>The CAG repeat within the androgen receptor gene and its relationship to prostate cancer</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>3320</fpage><lpage>3323</lpage><pub-id pub-id-type="pmid">9096391</pub-id><pub-id pub-id-type="doi">10.1073/pnas.94.7.3320</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Irvine</surname><given-names>RA</given-names></name><name><surname>Yu</surname><given-names>MC</given-names></name><name><surname>Ross</surname><given-names>RK</given-names></name><name><surname>Coetzee</surname><given-names>GA</given-names></name></person-group><article-title>The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><fpage>1937</fpage><lpage>1940</lpage><pub-id pub-id-type="pmid">7728763</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ingles</surname><given-names>SA</given-names></name><name><surname>Ross</surname><given-names>RK</given-names></name><name><surname>Yu</surname><given-names>MC</given-names></name><name><surname>Irvine</surname><given-names>RA</given-names></name><name><surname>La Pera</surname><given-names>G</given-names></name><name><surname>Haile</surname><given-names>RW</given-names></name><name><surname>Coetzee</surname><given-names>GA</given-names></name></person-group><article-title>Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor</article-title><source>J Natl Cancer Inst</source><year>1997</year><volume>89</volume><fpage>166</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">8998186</pub-id><pub-id pub-id-type="doi">10.1093/jnci/89.2.166</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stanford</surname><given-names>JL</given-names></name><name><surname>Just</surname><given-names>JJ</given-names></name><name><surname>Gibbs</surname><given-names>M</given-names></name><name><surname>Wicklund</surname><given-names>KG</given-names></name><name><surname>Neal</surname><given-names>CL</given-names></name><name><surname>Blumenstein</surname><given-names>BA</given-names></name><name><surname>Ostrander</surname><given-names>EA</given-names></name></person-group><article-title>Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>1194</fpage><lpage>1198</lpage><pub-id pub-id-type="pmid">9067292</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hakimi</surname><given-names>JM</given-names></name><name><surname>Schoenberg</surname><given-names>MP</given-names></name><name><surname>Rondinelli</surname><given-names>RH</given-names></name><name><surname>Piantadosi</surname><given-names>S</given-names></name><name><surname>Barrack</surname><given-names>ER</given-names></name></person-group><article-title>Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer</article-title><source>Clin Cancer Res</source><year>1997</year><volume>3</volume><fpage>1599</fpage><lpage>1608</lpage><pub-id pub-id-type="pmid">9815849</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ekman</surname><given-names>P</given-names></name><name><surname>Gronberg</surname><given-names>H</given-names></name><name><surname>Matsuyama</surname><given-names>H</given-names></name><name><surname>Kivineva</surname><given-names>M</given-names></name><name><surname>Bergerheim</surname><given-names>US</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group><article-title>Links between genetic and environmental factors and prostate cancer risk</article-title><source>Prostate</source><year>1999</year><volume>39</volume><fpage>262</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">10344215</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0045(19990601)39:4&#x0003c;262::AID-PROS6&#x0003e;3.0.CO;2-P</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsing</surname><given-names>AW</given-names></name><name><surname>Gao</surname><given-names>YT</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Sesterhenn</surname><given-names>IA</given-names></name><name><surname>Mostofi</surname><given-names>FK</given-names></name><name><surname>Benichou</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name></person-group><article-title>Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>5111</fpage><lpage>5116</lpage><pub-id pub-id-type="pmid">11016637</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rebbeck</surname><given-names>TR</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name><name><surname>Krithivas</surname><given-names>K</given-names></name><name><surname>Neuhausen</surname><given-names>S</given-names></name><name><surname>Blackwood</surname><given-names>MA</given-names></name><name><surname>Godwin</surname><given-names>AK</given-names></name><name><surname>Daly</surname><given-names>MB</given-names></name><name><surname>Narod</surname><given-names>SA</given-names></name><name><surname>Garber</surname><given-names>JE</given-names></name><name><surname>Lynch</surname><given-names>HT</given-names></name><etal></etal></person-group><article-title>Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat</article-title><source>Am J Hum Genet</source><year>1999</year><volume>64</volume><fpage>1371</fpage><lpage>1377</lpage><pub-id pub-id-type="pmid">10205268</pub-id><pub-id pub-id-type="doi">10.1086/302366</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spurdle</surname><given-names>AB</given-names></name><name><surname>Antoniou</surname><given-names>AC</given-names></name><name><surname>Duffy</surname><given-names>DL</given-names></name><name><surname>Pandeya</surname><given-names>N</given-names></name><name><surname>Kelemen</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Peock</surname><given-names>S</given-names></name><name><surname>Cook</surname><given-names>MR</given-names></name><name><surname>Smith</surname><given-names>PL</given-names></name><name><surname>Purdie</surname><given-names>DM</given-names></name><etal></etal></person-group><article-title>The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers</article-title><source>Breast Cancer Res</source><year>2005</year><volume>7</volume><fpage>R176</fpage><lpage>R183</lpage><pub-id pub-id-type="pmid">15743497</pub-id><pub-id pub-id-type="doi">10.1186/bcr971</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spurdle</surname><given-names>AB</given-names></name><name><surname>Dite</surname><given-names>GS</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Mayne</surname><given-names>CJ</given-names></name><name><surname>Southey</surname><given-names>MC</given-names></name><name><surname>Batten</surname><given-names>LE</given-names></name><name><surname>Chy</surname><given-names>H</given-names></name><name><surname>Trute</surname><given-names>L</given-names></name><name><surname>McCredie</surname><given-names>MR</given-names></name><name><surname>Giles</surname><given-names>GG</given-names></name><etal></etal></person-group><article-title>Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years</article-title><source>J Natl Cancer Inst</source><year>1999</year><volume>91</volume><fpage>961</fpage><lpage>966</lpage><pub-id pub-id-type="pmid">10359549</pub-id><pub-id pub-id-type="doi">10.1093/jnci/91.11.961</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dunning</surname><given-names>AM</given-names></name><name><surname>McBride</surname><given-names>S</given-names></name><name><surname>Gregory</surname><given-names>J</given-names></name><name><surname>Durocher</surname><given-names>F</given-names></name><name><surname>Foster</surname><given-names>NA</given-names></name><name><surname>Healey</surname><given-names>CS</given-names></name><name><surname>Smith</surname><given-names>N</given-names></name><name><surname>Pharoah</surname><given-names>PD</given-names></name><name><surname>Luben</surname><given-names>RN</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><etal></etal></person-group><article-title>No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer</article-title><source>Carcinogenesis</source><year>1999</year><volume>20</volume><fpage>2131</fpage><lpage>2135</lpage><pub-id pub-id-type="pmid">10545416</pub-id><pub-id pub-id-type="doi">10.1093/carcin/20.11.2131</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giguere</surname><given-names>Y</given-names></name><name><surname>Dewailly</surname><given-names>E</given-names></name><name><surname>Brisson</surname><given-names>J</given-names></name><name><surname>Ayotte</surname><given-names>P</given-names></name><name><surname>Laflamme</surname><given-names>N</given-names></name><name><surname>Demers</surname><given-names>A</given-names></name><name><surname>Forest</surname><given-names>VI</given-names></name><name><surname>Dodin</surname><given-names>S</given-names></name><name><surname>Robert</surname><given-names>J</given-names></name><name><surname>Rousseau</surname><given-names>F</given-names></name></person-group><article-title>Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>5869</fpage><lpage>5874</lpage><pub-id pub-id-type="pmid">11479228</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kadouri</surname><given-names>L</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Edwards</surname><given-names>S</given-names></name><name><surname>Hubert</surname><given-names>A</given-names></name><name><surname>Kote-Jarai</surname><given-names>Z</given-names></name><name><surname>Glaser</surname><given-names>B</given-names></name><name><surname>Durocher</surname><given-names>F</given-names></name><name><surname>Abeliovich</surname><given-names>D</given-names></name><name><surname>Peretz</surname><given-names>T</given-names></name><name><surname>Eeles</surname><given-names>RA</given-names></name></person-group><article-title>CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers</article-title><source>Br J Cancer</source><year>2001</year><volume>85</volume><fpage>36</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">11437399</pub-id><pub-id pub-id-type="doi">10.1054/bjoc.2001.1777</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeap</surname><given-names>BB</given-names></name><name><surname>Wilce</surname><given-names>JA</given-names></name><name><surname>Leedman</surname><given-names>PJ</given-names></name></person-group><article-title>The androgen receptor mRNA</article-title><source>Bioessays</source><year>2004</year><volume>26</volume><fpage>672</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">15170865</pub-id><pub-id pub-id-type="doi">10.1002/bies.20051</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brys</surname><given-names>M</given-names></name><name><surname>Wojcik</surname><given-names>M</given-names></name><name><surname>Romanowicz-Makowska</surname><given-names>H</given-names></name><name><surname>Krajewska</surname><given-names>WM</given-names></name></person-group><article-title>Androgen receptor status in female breast cancer: RT-PCR and Western blot studies</article-title><source>J Cancer Res Clin Oncol</source><year>2002</year><volume>128</volume><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">11862478</pub-id><pub-id pub-id-type="doi">10.1007/s004320100294</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Riboli</surname><given-names>E</given-names></name><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Haynes</surname><given-names>RB</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Kaaks</surname><given-names>R</given-names></name><name><surname>Stram</surname><given-names>DO</given-names></name><etal></etal></person-group><article-title>A candidate gene approach to searching for low-penetrance breast and prostate cancer genes</article-title><source>Nat Rev Cancer</source><year>2005</year><volume>5</volume><fpage>977</fpage><lpage>985</lpage><pub-id pub-id-type="pmid">16341085</pub-id><pub-id pub-id-type="doi">10.1038/nrc1754</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calle</surname><given-names>EE</given-names></name><name><surname>Rodriguez</surname><given-names>C</given-names></name><name><surname>Jacobs</surname><given-names>EJ</given-names></name><name><surname>Almon</surname><given-names>ML</given-names></name><name><surname>Chao</surname><given-names>A</given-names></name><name><surname>McCullough</surname><given-names>ML</given-names></name><name><surname>Feigelson</surname><given-names>HS</given-names></name><name><surname>Thun</surname><given-names>MJ</given-names></name></person-group><article-title>The American Cancer Society Prevention Study II Nutrition Cohort: rationale, study design and baseline characteristics</article-title><source>Cancer</source><year>2002</year><volume>94</volume><fpage>2490</fpage><lpage>2501</lpage><pub-id pub-id-type="pmid">12015775</pub-id><pub-id pub-id-type="doi">10.1002/cncr.101970</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riboli</surname><given-names>E</given-names></name><name><surname>Hunt</surname><given-names>KJ</given-names></name><name><surname>Slimani</surname><given-names>N</given-names></name><name><surname>Ferrari</surname><given-names>P</given-names></name><name><surname>Norat</surname><given-names>T</given-names></name><name><surname>Fahey</surname><given-names>M</given-names></name><name><surname>Charrondiere</surname><given-names>UR</given-names></name><name><surname>Hemon</surname><given-names>B</given-names></name><name><surname>Casagrande</surname><given-names>C</given-names></name><name><surname>Vignat</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection</article-title><source>Public Health Nutr</source><year>2002</year><volume>5</volume><fpage>1113</fpage><lpage>1124</lpage><pub-id pub-id-type="pmid">12639222</pub-id><pub-id pub-id-type="doi">10.1079/PHN2002394</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Colditz</surname><given-names>GA</given-names></name><name><surname>Hankinson</surname><given-names>SE</given-names></name></person-group><article-title>The Nurses' Health Study: lifestyle and health among women</article-title><source>Nat Rev Cancer</source><year>2005</year><volume>5</volume><fpage>388</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">15864280</pub-id><pub-id pub-id-type="doi">10.1038/nrc1608</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rexrode</surname><given-names>KM</given-names></name><name><surname>Lee</surname><given-names>IM</given-names></name><name><surname>Cook</surname><given-names>NR</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name></person-group><article-title>Baseline characteristics of participants in the Women's Health Study</article-title><source>J Womens Health Gend Based Med</source><year>2000</year><volume>9</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">10718501</pub-id><pub-id pub-id-type="doi">10.1089/152460900318911</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kolonel</surname><given-names>LN</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Hankin</surname><given-names>JH</given-names></name><name><surname>Nomura</surname><given-names>AM</given-names></name><name><surname>Wilkens</surname><given-names>LR</given-names></name><name><surname>Pike</surname><given-names>MC</given-names></name><name><surname>Stram</surname><given-names>DO</given-names></name><name><surname>Monroe</surname><given-names>KR</given-names></name><name><surname>Earle</surname><given-names>ME</given-names></name><name><surname>Nagamine</surname><given-names>FS</given-names></name></person-group><article-title>A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics</article-title><source>Am J Epidemiol</source><year>2000</year><volume>151</volume><fpage>346</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">10695593</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stram</surname><given-names>DO</given-names></name><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Kolonel</surname><given-names>LN</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Pike</surname><given-names>MC</given-names></name></person-group><article-title>Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study</article-title><source>Hum Hered</source><year>2003</year><volume>55</volume><fpage>27</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">12890923</pub-id><pub-id pub-id-type="doi">10.1159/000071807</pub-id></citation></ref><ref id="B44"><citation citation-type="other"><article-title>USC/Norris MEC Genetics homepage</article-title><ext-link ext-link-type="uri" xlink:href="http://www.uscnorris.com/mecgenetics/CohortGCKView.aspx"/></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Packer</surname><given-names>BR</given-names></name><name><surname>Yeager</surname><given-names>M</given-names></name><name><surname>Staats</surname><given-names>B</given-names></name><name><surname>Welch</surname><given-names>R</given-names></name><name><surname>Crenshaw</surname><given-names>A</given-names></name><name><surname>Kiley</surname><given-names>M</given-names></name><name><surname>Eckert</surname><given-names>A</given-names></name><name><surname>Beerman</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>E</given-names></name><name><surname>Bergen</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>SNP500 Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes</article-title><source>Nucleic Acids Res</source><year>2004</year><issue>32 Database</issue><fpage>D528</fpage><lpage>D532</lpage><pub-id pub-id-type="pmid">14681474</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkh005</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Hankinson</surname><given-names>SE</given-names></name><name><surname>Spiegelman</surname><given-names>D</given-names></name><name><surname>Colditz</surname><given-names>GA</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name></person-group><article-title>The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>1045</fpage><lpage>1049</lpage><pub-id pub-id-type="pmid">11861380</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Cox</surname><given-names>DG</given-names></name><name><surname>Paynter</surname><given-names>RA</given-names></name><name><surname>Hunter</surname><given-names>D</given-names></name><name><surname>De Vivo</surname><given-names>I</given-names></name></person-group><article-title>Accounting for haplotype uncertainty in association studies: a comparison of simple and flexible techniques</article-title><source>Genet Epidemiol</source><year>2005</year><volume>28</volume><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">15637718</pub-id><pub-id pub-id-type="doi">10.1002/gepi.20061</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zaykin</surname><given-names>DV</given-names></name><name><surname>Westfall</surname><given-names>PH</given-names></name><name><surname>Young</surname><given-names>SS</given-names></name><name><surname>Karnoub</surname><given-names>MA</given-names></name><name><surname>Wagner</surname><given-names>MJ</given-names></name><name><surname>Ehm</surname><given-names>MG</given-names></name></person-group><article-title>Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals</article-title><source>Hum Hered</source><year>2002</year><volume>53</volume><fpage>79</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">12037407</pub-id><pub-id pub-id-type="doi">10.1159/000057986</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>YC</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Nichols</surname><given-names>PW</given-names></name><name><surname>Zlotnikov</surname><given-names>G</given-names></name><name><surname>Jones</surname><given-names>PA</given-names></name><name><surname>Smith</surname><given-names>HS</given-names></name></person-group><article-title>Contiguous patches of normal human mammary epithelium derived from a single stem cell: implications for breast carcinogenesis</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>402</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">8542598</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15297300</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/bth457</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Linkage disequilibrium (LD) at androgen receptor (<italic>AR</italic>). Linkage disequilibrium plot generated by Haploview [50] showing correlation between all pairs of single nucleotide polymorphisms (SNPs) genotyped to select haplotype-tagging SNPs (ht-SNPs). The 32 SNPs genotyped among the 349 Multiethnic Cohort samples are shown in their physical position along the X chromosome (solid black horizontal line) and relative to the <italic>AR </italic>gene (depicted above the X chromosome plot). htSNPs selected are shown by arrows. Although two LD blocks are shown (black outline in LD plot), high correlation between the blocks allowed for the analysis of the htSNPs as one block.</p></caption><graphic xlink:href="bcr1602-1"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline characteristics of BPC3 participants by cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="2">ACS</td><td align="center" colspan="2">EPIC</td><td align="center" colspan="2">MEC</td><td align="center" colspan="2">NHS</td><td align="center" colspan="2">WHS</td><td align="center" colspan="2">All</td></tr></thead><tbody><tr><td></td><td align="center">Cases</td><td align="center">Controls</td><td align="center">Cases</td><td align="center">Controls</td><td align="center">Cases</td><td align="center">Controls</td><td align="center">Cases</td><td align="center">Controls</td><td align="center">Cases</td><td align="center">Controls</td><td align="center">Cases</td><td align="center">Controls</td></tr><tr><td colspan="13"><hr></hr></td></tr><tr><td align="left">Number</td><td align="center">503</td><td align="center">505</td><td align="center">1,719</td><td align="center">2,844</td><td align="center">1,617</td><td align="center">1,962</td><td align="center">1,059</td><td align="center">1,464</td><td align="center">705</td><td align="center">705</td><td align="center">5,603</td><td align="center">7,480</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Mean age in years at blood donation (standard deviation)</td><td align="center">68.9 (5.9)</td><td align="center">68.9 (5.8)</td><td align="center">55.4 (7.9)</td><td align="center">55.1 (8.3)</td><td align="center">66.4 (8.6)</td><td align="center">63.6 (8.7)</td><td align="center">57.6 (7.0)</td><td align="center">58.2 (6.9)</td><td align="center">56.0 (7.3)</td><td align="center">56.0 (7.3)</td><td align="center">60.2 (9.4)</td><td align="center">59.0 (9.0)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Mean body mass index (standard deviation)</td><td align="center">25.2 (4.6)</td><td align="center">25.5 (4.6)</td><td align="center">25.9 (4.4)</td><td align="center">26.1 (4.6)</td><td align="center">26.7 (5.6)</td><td align="center">27.0 (6.0)</td><td align="center">25.4 (4.7)</td><td align="center">25.6 (4.7)</td><td align="center">25.5 (4.4)</td><td align="center">26.0 (5.1)</td><td align="center">25.9 (4.9)</td><td align="center">26.2 (5.1)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Age in years at menarche</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02264;12</td><td align="center">46.9</td><td align="center">45.3</td><td align="center">35.5</td><td align="center">36.2</td><td align="center">53.9</td><td align="center">49.7</td><td align="center">42.4</td><td align="center">48.7</td><td align="center">56.7</td><td align="center">51.6</td><td align="center">47.8</td><td align="center">44.3</td></tr><tr><td align="left">13&#x02013;14</td><td align="center">43.9</td><td align="center">46.7</td><td align="center">48.5</td><td align="center">45.5</td><td align="center">35.5</td><td align="center">38.6</td><td align="center">39.5</td><td align="center">42.9</td><td align="center">37.0</td><td align="center">42.7</td><td align="center">41.1</td><td align="center">43.0</td></tr><tr><td align="left">15+</td><td align="center">9.3</td><td align="center">8.0</td><td align="center">16.0</td><td align="center">18.4</td><td align="center">10.5</td><td align="center">11.7</td><td align="center">8.1</td><td align="center">8.4</td><td align="center">6.2</td><td align="center">5.7</td><td align="center">11.0</td><td align="center">12.7</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Menopausal status</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Premenopausal</td><td align="center">0</td><td align="center">0</td><td align="center">24.3</td><td align="center">27.7</td><td align="center">11.0</td><td align="center">16.5</td><td align="center">19.4</td><td align="center">16.9</td><td align="center">21.7</td><td align="center">21.2</td><td align="center">17.0</td><td align="center">20.2</td></tr><tr><td align="left">Postmenopausal</td><td align="center">100</td><td align="center">100</td><td align="center">67.1</td><td align="center">63.6</td><td align="center">86.5</td><td align="center">81.8</td><td align="center">71.3</td><td align="center">74.8</td><td align="center">63.5</td><td align="center">60.2</td><td align="center">76.0</td><td align="center">72.7</td></tr><tr><td align="left">Perimenopausal/unknown</td><td align="center">0</td><td align="center">0</td><td align="center">8.6</td><td align="center">8.7</td><td align="center">2.5</td><td align="center">1.7</td><td align="center">9.4</td><td align="center">8.3</td><td align="center">14.8</td><td align="center">18.6</td><td align="center">7.0</td><td align="center">7.1</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Age in years at menopause*</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x0003c;40</td><td align="center">10.2</td><td align="center">9.9</td><td align="center">4.5</td><td align="center">5.0</td><td align="center">16.3</td><td align="center">18.9</td><td align="center">9.9</td><td align="center">11.1</td><td align="center">7.1</td><td align="center">9.0</td><td align="center">10.6</td><td align="center">11.4</td></tr><tr><td align="left">40&#x02013;44</td><td align="center">10.2</td><td align="center">12.4</td><td align="center">9.5</td><td align="center">10.3</td><td align="center">14.9</td><td align="center">16.9</td><td align="center">12.2</td><td align="center">11.3</td><td align="center">10.0</td><td align="center">14.5</td><td align="center">12.0</td><td align="center">13.1</td></tr><tr><td align="left">45&#x02013;49</td><td align="center">20.4</td><td align="center">28.2</td><td align="center">28.9</td><td align="center">31.8</td><td align="center">26.6</td><td align="center">27.9</td><td align="center">27.6</td><td align="center">28.1</td><td align="center">31.1</td><td align="center">31.6</td><td align="center">27.0</td><td align="center">29.4</td></tr><tr><td align="left">50&#x02013;54</td><td align="center">46.6</td><td align="center">39.7</td><td align="center">47.1</td><td align="center">44.0</td><td align="center">32.8</td><td align="center">29.0</td><td align="center">44.5</td><td align="center">43.7</td><td align="center">43.9</td><td align="center">36.8</td><td align="center">41.3</td><td align="center">38.4</td></tr><tr><td align="left">55+</td><td align="center">12.6</td><td align="center">9.9</td><td align="center">10.0</td><td align="center">8.9</td><td align="center">9.4</td><td align="center">7.3</td><td align="center">5.8</td><td align="center">5.8</td><td align="center">7.8</td><td align="center">8.0</td><td align="center">9.1</td><td align="center">7.8</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Parous women</td><td align="center">91.0</td><td align="center">91.4</td><td align="center">86.7</td><td align="center">86.8</td><td align="center">85.5</td><td align="center">88.8</td><td align="center">92.3</td><td align="center">93.3</td><td align="center">84.8</td><td align="center">86.2</td><td align="center">87.5</td><td align="center">88.9</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Family history</td><td align="center">20.7</td><td align="center">15.5</td><td align="center">-</td><td align="center">-</td><td align="center">17.1</td><td align="center">11.1</td><td align="center">19.2</td><td align="center">13.9</td><td align="center">20.1</td><td align="center">16.3</td><td align="center">18.6</td><td align="center">13.3</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Ever HRT use*</td><td align="center">67.0</td><td align="center">58.7</td><td align="center">42.3</td><td align="center">34.1</td><td align="center">63.9</td><td align="center">58.9</td><td align="center">77.2</td><td align="center">72.0</td><td align="center">68.0</td><td align="center">60.3</td><td align="center">61.4</td><td align="center">53.5</td></tr><tr><td align="left">Carcinoma <italic>in situ</italic></td><td align="center">21.5</td><td align="center">-</td><td align="center">6.3</td><td align="center">-</td><td align="center">1.0</td><td align="center">-</td><td align="center">0</td><td align="center">-</td><td align="center">0</td><td align="center">-</td><td align="center">4.1</td><td align="center">-</td></tr><tr><td align="left">ER-positive</td><td align="center">52.7</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">62.0</td><td align="center">-</td><td align="center">68.0</td><td align="center">-</td><td align="center">80.4</td><td align="center">-</td><td align="center">65.8</td><td align="center">-</td></tr><tr><td align="left">PR-positive</td><td align="center">44.5</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">51.1</td><td align="center">-</td><td align="center">57.5</td><td align="center">-</td><td align="center">71.9</td><td align="center">-</td><td align="center">55.8</td><td align="center">-</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Ethnicity</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">White</td><td align="center">97.8</td><td align="center">98.6</td><td align="center">100</td><td align="center">100</td><td align="center">24.8</td><td align="center">22.4</td><td align="center">93.6</td><td align="center">93.6</td><td align="center">95.6</td><td align="center">95.6</td><td align="center">76.3</td><td align="center">77.9</td></tr><tr><td align="left">Hispanic</td><td align="center">0.8</td><td align="center">0.2</td><td align="center">0</td><td align="center">0</td><td align="center">20.8</td><td align="center">19.7</td><td align="center">0.1</td><td align="center">0.3</td><td align="center">0.6</td><td align="center">0.6</td><td align="center">6.2</td><td align="center">5.3</td></tr><tr><td align="left">African-American</td><td align="center">0.8</td><td align="center">0.8</td><td align="center">0</td><td align="center">0</td><td align="center">21.3</td><td align="center">21.7</td><td align="center">0.8</td><td align="center">0.6</td><td align="center">0.7</td><td align="center">0.7</td><td align="center">6.5</td><td align="center">5.9</td></tr><tr><td align="left">Asian</td><td align="center">0.4</td><td align="center">0.4</td><td align="center">0</td><td align="center">0</td><td align="center">26.3</td><td align="center">21.4</td><td align="center">0.1</td><td align="center">0.4</td><td align="center">1.0</td><td align="center">1.0</td><td align="center">7.8</td><td align="center">5.8</td></tr><tr><td align="left">Hawaiian</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">6.7</td><td align="center">14.8</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.0</td><td align="center">3.9</td></tr><tr><td align="left">Other</td><td align="center">0.2</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">5.5</td><td align="center">5.1</td><td align="center">2.1</td><td align="center">2.1</td><td align="center">1.3</td><td align="center">1.2</td></tr></tbody></table><table-wrap-foot><p>ACS, American Cancer Society; BPC3, Breast and Prostate Cancer Cohort Consortium; EPIC, European Prospective Investigation into Cancer and Nutrition; ER, oestrogen receptor; HRT, hormone replacement therapy; MEC, Multiethnic Cohort; NHS, Nurses' Health Study; PR, progesterone receptor; WHS, Women's Health Study.</p><p>* Among post-menopausal women only</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Association between breast cancer and individual htSNPs in the <italic>AR </italic>across the BPC3 cohorts</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">SNP</td><td align="center">Genotype</td><td align="center">Cases (percentage)<sup>a</sup></td><td align="center">Controls (percentage)<sup>a</sup></td><td align="center">OR (95% CI)<sup>b</sup></td><td align="center"><italic>P </italic>trend<sup>c</sup></td><td align="center"><italic>P </italic>heterogeneity<sup>d</sup></td></tr></thead><tbody><tr><td align="center">AR_001</td><td align="center">AA</td><td align="center">4,480 (82)</td><td align="center">6,034 (83)</td><td align="center">1.00 (Ref.)</td><td align="center">.</td><td align="center">.</td></tr><tr><td align="center">rs962458</td><td align="center">AG</td><td align="center">826 (15)</td><td align="center">1,054 (14)</td><td align="center">1.04 (0.95 to 1.15)</td><td align="center">.</td><td align="center">.</td></tr><tr><td></td><td align="center">GG</td><td align="center">146 (3)</td><td align="center">187 (3)</td><td align="center">1.02 (0.83 to 1.26)</td><td align="center">0.50</td><td align="center">0.96</td></tr><tr><td align="center">AR_002</td><td align="center">GG</td><td align="center">3,833 (71)</td><td align="center">5,073 (70)</td><td align="center">1.00 (Ref.)</td><td align="center">.</td><td align="center">.</td></tr><tr><td align="center">rs6152</td><td align="center">GA</td><td align="center">1,324 (25)</td><td align="center">1,815 (25)</td><td align="center">0.98 (0.90 to 1.06)</td><td align="center">.</td><td align="center">.</td></tr><tr><td></td><td align="center">AA</td><td align="center">245 (5)</td><td align="center">314 (4)</td><td align="center">1.02 (0.87 to 1.20)</td><td align="center">0.89</td><td align="center">0.84</td></tr><tr><td align="center">AR_003</td><td align="center">GG</td><td align="center">3,773 (70)</td><td align="center">4,984 (69)</td><td align="center">1.00 (Ref.)</td><td align="center">.</td><td align="center">.</td></tr><tr><td align="center">rs1204038</td><td align="center">GA</td><td align="center">1,279 (24)</td><td align="center">1,762 (24)</td><td align="center">0.97 (0.90 to 1.06)</td><td align="center">.</td><td align="center">.</td></tr><tr><td></td><td align="center">AA</td><td align="center">365 (7)</td><td align="center">452 (6)</td><td align="center">1.05 (0.89 to 1.23)</td><td align="center">0.96</td><td align="center">0.86</td></tr><tr><td align="center">AR_004</td><td align="center">AA</td><td align="center">4,940 (90)</td><td align="center">6,540 (90)</td><td align="center">1.00 (Ref.)</td><td align="center">.</td><td align="center">.</td></tr><tr><td align="center">rs2361634</td><td align="center">AG</td><td align="center">524 (9)</td><td align="center">727 (10)</td><td align="center">0.95 (0.85 to 1.07)</td><td align="center">.</td><td align="center">.</td></tr><tr><td></td><td align="center">GG</td><td align="center">25 (&#x0003c;1)</td><td align="center">24 (&#x0003c;1)</td><td align="center">1.30 (0.76 to 2.21)</td><td align="center">0.70</td><td align="center">0.56</td></tr><tr><td align="center">AR_005</td><td align="center">AA</td><td align="center">4,601 (84)</td><td align="center">6,188 (85)</td><td align="center">1.00 (Ref.)</td><td align="center">.</td><td align="center">.</td></tr><tr><td align="center">rs1337080</td><td align="center">AG</td><td align="center">802 (15)</td><td align="center">1,012 (14)</td><td align="center">1.07 (0.97 to 1.18)</td><td align="center">.</td><td align="center">.</td></tr><tr><td></td><td align="center">GG</td><td align="center">65 (1)</td><td align="center">81 (1)</td><td align="center">1.06 (0.80 to 1.41)</td><td align="center">0.20</td><td align="center">0.88</td></tr><tr><td align="center">AR_006</td><td align="center">AA</td><td align="center">3,442 (63)</td><td align="center">4,596 (63)</td><td align="center">1.00 (Ref.)</td><td align="center">.</td><td align="center">.</td></tr><tr><td align="center">rs1337082</td><td align="center">AG</td><td align="center">1,601 (29)</td><td align="center">2,154 (29)</td><td align="center">1.01 (0.94 to 1.09)</td><td align="center">.</td><td align="center">.</td></tr><tr><td></td><td align="center">GG</td><td align="center">416 (8)</td><td align="center">556 (8)</td><td align="center">0.99 (0.85 to 1.14)</td><td align="center">0.97</td><td align="center">0.29</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Numbers of cases and controls genotyped for each SNP vary due to assay failure; <sup>b</sup>unadjusted logistic regression, conditional on matching factors and cohort as described in text; <sup>c</sup>test for trend for log-additive or codominant model; <sup>d</sup>test for heterogeneity in ORs across cohorts. AR, androgen receptor; BPC3, Breast and Prostate Cancer Cohort Consortium; CI, confidence interval; htSNP, haplotype-tagging single nucleotide polymorphism; OR, odds ratio; Ref., Reference category; SNP, single nucleotide polymorphism.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Association between AR haplotypes and breast cancer risk in the NCI BPC3</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Haplotype</td><td align="center">Percentage in cases (<italic>n </italic>= 5,584)</td><td align="center">Percentage in controls (<italic>n </italic>= 7,459)</td><td align="center">OR<sup>a </sup>(95% CI)</td></tr></thead><tbody><tr><td align="center">AGGAAA</td><td align="center">0.72</td><td align="center">0.71</td><td align="center">1.00 (Ref.)</td></tr><tr><td align="center">GAAAGG</td><td align="center">0.08</td><td align="center">0.08</td><td align="center">1.01 (0.93 to 1.11)</td></tr><tr><td align="center">AAAAAG</td><td align="center">0.06</td><td align="center">0.07</td><td align="center">0.94 (0.85 to 1.03)</td></tr><tr><td align="center">AGGGAA</td><td align="center">0.05</td><td align="center">0.05</td><td align="center">0.97 (0.87 to 1.08)</td></tr><tr><td align="center">AGGAAG</td><td align="center">0.05</td><td align="center">0.05</td><td align="center">1.02 (0.91 to 1.15)</td></tr><tr><td align="center">GAAAAG</td><td align="center">0.02</td><td align="center">0.02</td><td align="center">0.99 (0.83 to 1.18)</td></tr><tr><td align="center">AGAAAG</td><td align="center">0.02</td><td align="center">0.01</td><td align="center">0.98 (0.82 to 1.18)</td></tr><tr><td align="center">&#x0003c;5%</td><td align="center">0.02</td><td align="center">0.01</td><td align="center">1.18 (0.98 to 1.43)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Unadjusted logistic regression, conditional on matching factors and cohort as described in text. AR, androgen receptor; CI, confidence interval; NCI BPC3, National Cancer Institute Breast and Prostate Cancer Cohort Consortium; OR, odds ratio; Ref., Reference category.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>AR exon 1 CAG Repeat length and family history in the NHS and the WHS</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Family history</td><td align="center">Genotype<sup>a </sup>[CAG]<sub>n</sub></td><td align="center">1990&#x02013;1996 OR (95% CI)<sup>b</sup></td><td align="center">1998&#x02013;2000 OR (95% CI)<sup>b</sup></td><td align="center">WHS OR (95% CI)<sup>b</sup></td><td align="center">NHS and WHS Combined OR (95% CI)<sup>b</sup></td></tr></thead><tbody><tr><td align="center">no</td><td align="center">&#x0003c;22</td><td align="center">1.0 (Ref.)</td><td align="center">1.0 (Ref.)</td><td align="center">1.0 (Ref.)</td><td align="center">1.0 (Ref.)</td></tr><tr><td align="center">no</td><td align="center">&#x02265;22</td><td align="center">0.9 (0.8 to 1.2)</td><td align="center">1.0 (0.7 to 1.4)</td><td align="center">0.7 (0.5 to 1.0)</td><td align="center">1.0 (0.9 to 1.2)</td></tr><tr><td align="center">yes</td><td align="center">&#x0003c;22</td><td align="center">1.0 (0.6 to 1.7)</td><td align="center">2.0 (0.9 to 4.2)</td><td align="center">1.6 (0.8 to 3.0)</td><td align="center">1.1 (0.9 to 1.5)</td></tr><tr><td align="center">yes</td><td align="center">&#x02265;22</td><td align="center">1.7 (1.2 to 2.4)</td><td align="center">1.6 (0.9 to 2.6)</td><td align="center">1.1 (0.7 to 1.8)</td><td align="center">1.3 (1.1 to 1.6)</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">no</td><td align="center">&#x0003c;22</td><td align="center">1.0 (Ref.)</td><td align="center">1.0 (Ref.)</td><td align="center">1.0 (Ref.)</td><td align="center">1.0 (Ref.)</td></tr><tr><td align="center">no</td><td align="center">&#x02265;23</td><td align="center">0.9 (0.7 to1.2)</td><td align="center">0.9 (0.7 to 1.3)</td><td align="center">0.7 (0.5 to 1.0)</td><td align="center">1.0 (0.9 to 1.2)</td></tr><tr><td align="center">yes</td><td align="center">&#x0003c;22</td><td align="center">1.0 (0.8 to 1.4)</td><td align="center">1.9 (0.9 to 4.1)</td><td align="center">1.6 (0.8 to 3.0)</td><td align="center">1.1 (0.9 to 1.5)</td></tr><tr><td align="center">yes</td><td align="center">&#x02265;23</td><td align="center">1.8 (1.2 to 2.5)</td><td align="center">1.5 (0.9 to 2.6)</td><td align="center">1.0 (0.6 to 1.5)</td><td align="center">1.4 (1.1 to 1.8)</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">no</td><td align="center">&#x0003c;22</td><td align="center">1.00 (Ref.)</td><td align="center">1.0 (Ref.)</td><td align="center">1.0 (Ref.)</td><td align="center">1.0 (Ref.)</td></tr><tr><td align="center">no</td><td align="center">&#x02265;25</td><td align="center">1.0 (0.8 to 1.4)</td><td align="center">0.9 (0.6 to 1.3)</td><td align="center">0.7 (0.5 to 1.1)</td><td align="center">1.0 (0.9 to 1.2)</td></tr><tr><td align="center">yes</td><td align="center">&#x0003c;22</td><td align="center">1.1 (0.6 to 1.8)</td><td align="center">1.8 (0.9 to 4.0)</td><td align="center">1.6 (0.8 to 3.0)</td><td align="center">1.1 (0.9 to 1.5)</td></tr><tr><td align="center">yes</td><td align="center">&#x02265;25</td><td align="center">2.0 (1.3 to 3.1)</td><td align="center">1.5 (0.7 to 3.0)</td><td align="center">0.7 (0.4 to 1.3)</td><td align="center">1.5 (1.1 to 2.0)</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">no</td><td align="center">&#x0003c;22</td><td align="center">1.0 (Ref.)</td><td align="center">1.0 (Ref.)</td><td align="center">1.0 (Ref.)</td><td align="center">1.0 (Ref.)</td></tr><tr><td align="center">no</td><td align="center">&#x02265;27</td><td align="center">1.1 (0.7 to 1.7)</td><td align="center">1.4 (0.8 to 2.5)</td><td align="center">0.8 (0.5 to 1.3)</td><td align="center">1.1 (0.9 to 1.4)</td></tr><tr><td align="center">yes</td><td align="center">&#x0003c;22</td><td align="center">1.1 (0.6 to 1.9)</td><td align="center">2.0 (0.9 to 4.6)</td><td align="center">1.6 (0.8 to 3.0)</td><td align="center">1.1 (0.9 to 1.6)</td></tr><tr><td align="center">yes</td><td align="center">&#x02265;27</td><td align="center">1.6 (0.8 to 3.1)</td><td align="center">2.1 (0.7 to 6.5)</td><td align="center">0.7 (0.3 to 1.8)</td><td align="center">1.4 (0.9 to 2.1)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>AR genotype defined as having one or more long alleles &#x02265;22, 23, 25, or 27 versus both alleles &#x0003c;22; <sup>b</sup>unconditional, unadjusted logistic regression. AR, androgen receptor; CI, confidence interval; NHS, Nurses' Health Study; OR, odds ratio; Ref., Reference category; WHS, Women's Health Study.</p></table-wrap-foot></table-wrap></sec></back></article> 